Plasminogen mediates the pathological effects of urokinase-type plasminogen activator overexpression

被引:24
|
作者
Bolon, I [1 ]
Zhou, HM [1 ]
Charron, Y [1 ]
Wohlwend, A [1 ]
Vassalli, JD [1 ]
机构
[1] Univ Geneva, Ctr Med, Sch Med, Dept Morphol, CH-1211 Geneva 4, Switzerland
来源
AMERICAN JOURNAL OF PATHOLOGY | 2004年 / 164卷 / 06期
关键词
D O I
10.1016/S0002-9440(10)63786-8
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Increased expression of urokinase-type plasminogen activator (uPA) and its receptor (uPAR) is associated with different pathological conditions. Both uPAR-mediated signaling and plasmin-catalyzed extracellular proteolysis may contribute to pathogenesis. To evaluate the involvement of plasminogen in such circumstances, we have taken advantage of transgenic mouse models in which overexpression of uPA and/or uPAR in enamel epithelium, basal epidermis, and hair follicles leads to a pathological phenotype; uPA transgenic mice have chalky-white incisors and, when uPAR is co-expressed, develop extensive alopecia, epidermal thickening, and subepidermal blisters. We report here that when these transgenic mice were backcrossed into a plasminogen-deficient (Plg(-/-)) background, the dental and skin phenotypes appeared completely normal. Heterozygous Plg+/- transgenic mice exhibited a haplo-insufficiency, with an intermediate or normal phenotype. These results do not argue in favor of a role for uPAR-mediated signaling in our experimental model; rather, they demonstrate an essential, dose-dependent, requirement for plasminogen in uPA-mediated tissue alterations. They also support the hypothesis that plasminogen could play a part in certain skin diseases.
引用
收藏
页码:2299 / 2304
页数:6
相关论文
共 50 条
  • [21] Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: Correlation with tumor associated macrophage and prognosis
    Ohba, K
    Miyata, Y
    Kanda, S
    Koga, S
    Hayashi, T
    Kanetake, H
    JOURNAL OF UROLOGY, 2005, 174 (02): : 461 - 465
  • [22] UROKINASE-TYPE PLASMINOGEN-ACTIVATOR, UROKINASE-TYPE PLASMINOGEN-ACTIVATOR RECEPTOR AND PLASMINOGEN-ACTIVATOR INHIBITOR-1 I IN BREAST-CANCER CELLS
    WAJIMA, T
    DEGEN, D
    ORIZ, V
    VONHOFFOLIN, DD
    THROMBOSIS AND HAEMOSTASIS, 1995, 73 (06) : 1284 - 1284
  • [23] Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system
    Yin, SP
    Lockett, J
    Meng, YH
    Biliran, H
    Blouse, GE
    Li, XH
    Reddy, N
    Zhao, ZM
    Lin, XL
    Anagli, J
    Cher, ML
    Sheng, SJ
    CANCER RESEARCH, 2006, 66 (08) : 4173 - 4181
  • [24] Evaluation of plasma urokinase-type plasminogen activator and urokinase-type plasminogen-activator receptor in patients with acute and chronic hepatitis B
    Zhou, Huanqin
    Wu, Xianguo
    Lu, Xingguo
    Chen, Gang
    Ye, Xiongwei
    Huang, Jian
    THROMBOSIS RESEARCH, 2009, 123 (03) : 537 - 542
  • [25] Urokinase-type plasminogen activator receptor: A beacon of malignancy?
    Drapkin, Ronny
    Clauss, Adam
    Skates, Steven
    CLINICAL CANCER RESEARCH, 2008, 14 (18) : 5643 - 5645
  • [26] Small molecule inhibitors of urokinase-type plasminogen activator
    Rockway, TW
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2003, 13 (06) : 773 - 786
  • [27] Urokinase-type plasminogen activator receptor in IgA nephropathy
    Ahn, Shin-Young
    Chin, Ho Jun
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2014, 29 (02): : 166 - 169
  • [28] Structure, function and antagonists of urokinase-type plasminogen activator
    Carriero, Maria Vincenza
    Franco, Paola
    Vocca, Imma
    Alfano, Daniela
    Votta, Giuseppina
    Longanesi-Cattani, Immacolata
    Bifulco, Katia
    Mancini, Alessandro
    Caputi, Mario
    Stoppelli, Maria Patrizia
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2009, 14 : 3782 - 3794
  • [29] Identification of a novel inhibitor of urokinase-type plasminogen activator
    Zhu, Ming
    Gokhale, Vijay M.
    Szabo, Lajos
    Munoz, Ruben M.
    Baek, Hyounggee
    Bashyam, Sridevi
    Hurley, Laurence H.
    Von Hoff, Daniel D.
    Han, Haiyong
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (04) : 1348 - 1356
  • [30] Properties of the urokinase-type plasminogen activator modified with phenylglyoxal
    Moukhametova, LI
    Aisina, RB
    Lomakina, GY
    Varfolomeev, SD
    RUSSIAN JOURNAL OF BIOORGANIC CHEMISTRY, 2002, 28 (04) : 278 - 283